(CADL) Candel Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 643m USD | Total Return: 47.4% in 12m
Avg Turnover: 15.6M
Warnings
Share dilution 96.9% YoY
Interest Coverage Ratio -17.8 is critical
Altman Z'' -4.30 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
Leader
Candel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for solid tumors. The company’s pipeline is led by CAN-2409, currently in Phase 2 trials for prostate and non-small cell lung cancer, and CAN-3110, which targets recurrent high-grade glioma in Phase 1 trials. Its proprietary enLIGHTEN Discovery Platform utilizes a herpes simplex virus framework combined with advanced analytics to generate new therapeutic candidates.
The biotechnology sector often faces high capital expenditures and long developmental timelines, as clinical-stage firms typically operate without product revenue while awaiting regulatory approvals. Candel’s business model relies on the successful transition of its viral candidates through the FDA clinical trial phases to reach commercialization or licensing milestones. Investors seeking deeper fundamental analysis may find ValueRay useful for further due diligence. Formerly known as Advantagene, Inc., the company has been headquartered in Needham, Massachusetts, since its incorporation in 2003.
- Phase 2 clinical trial data readouts for CAN-2409 in prostate and lung cancer
- FDA regulatory milestones and potential fast track designations for viral immunotherapy candidates
- Cash runway and future equity financing requirements to fund ongoing clinical operations
- Clinical progress of CAN-3110 in high-grade glioma Phase 1 trials
- Strategic partnerships or licensing deals involving the enLIGHTEN discovery platform technology
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA 10.00 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.24 > 3% & CFO -47.7m > Net Income -54.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 28.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.4m) vs 12m ago 96.88% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.04%; Δ -1.04% > 0%) |
| Interest Coverage Ratio: -17.78 > 6 (EBITDA TTM -59.3m / Interest Expense TTM 3.38m) |
| A: 0.94 (Total Current Assets 197.8m - Total Current Liabilities 7.05m) / Total Assets 201.9m |
| B: -1.18 (Retained Earnings -239.2m / Total Assets 201.9m) |
| C: -0.40 (EBIT TTM -60.0m / Avg Total Assets 148.9m) |
| D: -3.73 (Book Value of Equity -238.5m / Total Liabilities 63.9m) |
| Altman-Z'' = -4.30 = D |
As of May 24, 2026, the stock is trading at USD 7.93 with a total of 1,671,247 shares traded.
Over the past week, the price has changed by -8.89%,
over one month by +8.86%,
over three months by +60.76% and
over the past year by +47.42%.
Candel Therapeutics has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy CADL.
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.9 | 138.1% |
P/S = 436.4156
P/B = 11.7832
Revenue TTM = 0.0 USD
EBIT TTM = -60.0m USD
EBITDA TTM = -59.3m USD
Long Term Debt = 47.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 453k USD (from shortTermDebt, last quarter)
Debt = 49.5m USD (corrected: LT Debt 47.1m + ST Debt 453k) + Leases 1.90m
Net Debt = -90.3m USD (calculated: Debt 49.5m - CCE 139.8m)
Enterprise Value = 552.2m USD (642.6m + Debt 49.5m - CCE 139.8m)
Interest Coverage Ratio = -17.78 (Ebit TTM -60.0m / Interest Expense TTM 3.38m)
EV/FCF = -10.74x (Enterprise Value 552.2m / FCF TTM -51.4m)
FCF Yield = -9.31% (FCF TTM -51.4m / Enterprise Value 552.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 749k) / Revenue TTM)
Tobins Q-Ratio = 2.73 (Enterprise Value 552.2m / Total Assets 201.9m)
Interest Expense / Debt = 6.82% (Interest Expense 3.38m / Debt 49.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -47.4m (EBIT -60.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.60 (Total Current Assets 197.8m / Total Current Liabilities 10.1m)
Debt / Equity = 0.36 (Debt 49.5m / totalStockholderEquity, last quarter 138.0m)
Debt / EBITDA = 1.52 (negative EBITDA) (Net Debt -90.3m / EBITDA -59.3m)
Debt / FCF = 1.76 (negative FCF - burning cash) (Net Debt -90.3m / FCF TTM -51.4m)
Total Stockholder Equity = 90.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.55% (Net Income -54.4m / Total Assets 201.9m)
RoE = -16.53% (Net Income TTM -54.4m / Total Stockholder Equity 329.3m)
RoCE = -15.95% (EBIT -60.0m / Capital Employed (Equity 329.3m + L.T.Debt 47.1m))
RoIC = -85.46% (negative operating profit) (NOPAT -47.4m / Invested Capital 55.5m)
WACC = 13.38% (E(642.6m)/V(692.1m) * Re(14.0%) + D(49.5m)/V(692.1m) * Rd(6.82%) * (1-Tc(0.21)))
Discount Rate = 14.0% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 40.58%
[DCF] Fair Price = unknown (Cash Flow -51.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.32 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.24 | Chg30d=+35.04% | Revisions=-43% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.26 | Chg30d=+31.89% | Revisions=-43% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.74 | Chg30d=+3.90% | Revisions=-20% | GrowthEPS=+15.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.21 | Chg30d=+67.19% | Revisions=-20% | GrowthEPS=+71.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -43%